8-K/A 1 aggx8ka050709apg.htm AGGX 8-K/A 05-07-09 AGGX 8-K/A 05-07-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION


Washington, DC 20549

___________

 

FORM 8-K/A

___________

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): May 7, 2009

 

Commission File Number: 000-26181


AngioGenex, Inc.

 (Exact name of small business issuer as specified in its charter)


Nevada

 

86-0945116

(State or other jurisdiction of incorporation or organization)

 

(IRS Employer Identification No.)


425 Madison Ave., Suite 902, New York, New York 10017

(Address of principal executive offices)


(212) 874-6008

(Issuer's telephone number, including area code)


 

(Former name, former address and former fiscal year,

If changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[ ]

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 

 



Section 4. Matters Related to Accountants and Financial Statements


Item 4.01 Changes in Registrant's Certifying Accountant.


(1)

This amendment to the Report on Form 8-K that was originally filed with the SEC on May 4, 2009, is a correction to the previous filing because it was filed erroneously due to a miscommunication between AngioGenex and the EDGAR filer service.  This original filing was an unfinished draft that was filed prematurely and there has been no change in the Company’s Independent Registered Public Accounting Firm as suggested in the aforementioned 8-K.


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


AngioGenex, Inc. (Registrant)


Date: May 7, 2009

By: /s/ Bill Garland

Bill Garland

President and Chief Executive Officer